Imperial College London
Alternate

Professor Sir Roy Anderson FRS, FMedSci

Faculty of Medicine, School of Public Health

Professor in Infectious Disease Epidemiology
 
 
 
//

Contact

 

roy.anderson Website

 
 
//

Assistant

 

Mrs Clare Mylchreest +44 (0)7766 331 301

 
//

Location

 

LG35Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lawrence:2017:10.3233/JAD-170261,
author = {Lawrence, E and Vegvari, C and Ower, A and Hadjichrysanthou, C and De, Wolf F and Anderson, RM},
doi = {10.3233/JAD-170261},
journal = {JOURNAL OF ALZHEIMERS DISEASE},
pages = {1359--1379},
title = {A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers},
url = {http://dx.doi.org/10.3233/JAD-170261},
volume = {59},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disease, with no effective treatment orcure. A gold standard therapy would be treatment to slow or halt disease progression; however, knowledge of causationin the early stages of AD is very limited. In order to determine effective endpoints for possible therapies, a number ofquantitative surrogate markers of disease progression have been suggested, including biochemical and imaging biomarkers.The dynamics of these various surrogate markers over time, particularly in relation to disease development, are, however,not well characterized. We reviewed the literature for studies that measured cerebrospinal fluid or plasma amyloid-andtau, or took magnetic resonance image or fluorodeoxyglucose/Pittsburgh compound B-positron electron tomography scans,in longitudinal cohort studies. We summarized the properties of the major cohort studies in various countries, commonlyused diagnosis methods and study designs. We have concluded that additional studies with repeat measures over time in arepresentative population cohort are needed to address the gap in knowledge of AD progression. Based on our analysis, wesuggest directions in which research could move in order to advance our understanding of this complex disease, includingrepeat biomarker measurements, standardization and increased sample sizes.
AU  - Lawrence,E
AU  - Vegvari,C
AU  - Ower,A
AU  - Hadjichrysanthou,C
AU  - De,Wolf F
AU  - Anderson,RM
DO  - 10.3233/JAD-170261
EP  - 1379
PY  - 2017///
SN  - 1387-2877
SP  - 1359
TI  - A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers
T2  - JOURNAL OF ALZHEIMERS DISEASE
UR  - http://dx.doi.org/10.3233/JAD-170261
UR  - http://hdl.handle.net/10044/1/54562
VL  - 59
ER  -
Download